Sanofi In Pole Position In Oral Type 1 Diabetes With Zynquista Filings

The French drugmaker and partner Lexicon now have a PDUFA date of March 22 next year for their dual inhibitor of SGLT-1 and SGLT-2 which is well placed to become the first oral antidiabetic to get the green light for use by adults with the type 1 form of the disease, in combination with insulin.

Motor racing
Zynquista heads type 1 diabetes oral therapy race • Source: Shutterstock

More from Clinical Trials

More from R&D